Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I can’t wait when news comes out. We will wake up one morning with a lot of extra money in our accounts. With the type of companies that icahn knows, I think we will see multi dollars for ENZN
$ENZN has a lot going for it. With the corporate tax rate going up soon, I think companies wanting to go public via SPAC will want to use NOL mini SPAC like ENZN instead of the traditional SPAC’s
It would be extremely easy to get this listed on Nasdaq when the time comes.
Interesting. I wasn’t watching L2 yesterday. Was it big buy blocks that were going through when it went to .35?
I noticed that OTC website shows 200k bid at .30 and a 30k bid at .31
The Q4 results should come out next month. Hopefully we get a hint of something.
My favorite part of the last PR is this from the current CEO that is retiring next month:
“I have no doubt that Enzon has an impressive and exciting future,” Rackear said.
I bought in this morning! Can’t thank you enough for seeing your short interest and Cramer posts! How high do you see this going? And is there really over 100% short interest?
Very interesting. It looks like VLTC had a 250%+ run as Icahn was buying shares. That one also had a over $100 million NOL like ENZN so I can see why Icahn likes these.
It’s perfect for tax free income for profitable companies.
I will try and dig around a little more too
I definitely think ENZN will be a multi dollar stock when Carl Icahn and crew find a company to buy.
Not only that but if Sesen’s drug gets approved, which sounds like will, in the next few months then ENZN will get 3.5 million milestone payment and millions of dollars worth of royalty payments each year for the next 10 years.
That is one of many reasons I like this stock. Looks like we closed at a new 52 week high today. Hopefully the trend continues.
A bigger question is who is buying all the sells you mention. Icahn owns nearly half the OS so I think he will make sure we get a good deal here.
He is talking about a form 4. Insiders have to file them if they buy or sell a stock.
I definitely think Icahn and Couchman are in contact with each other. With them combined they own a large majority of the shares outstanding. I’m sure they are discussing together, any potential deal since they would easily have enough voting power to make the deal happen.
And yes, the fact that Couchman has not moved on is a good thing. Big things will happen here with $ENZN.
I told Elon Musk to consider using $MYRX as a holding company since it has $150 million NOL’s to offset its profits. Doubt he will mention it but if he ever did I would be a multi millionaire overnight lol
I’m jealous of the amount of shares that you have. I hope we get news in the next month or so. The current CEO is retiring at the end of February so maybe then? Makes sense that they aren’t replacing management, just promoting within. They won’t be needed once ENZN buys a company that has existing management already in place
You should add ENZN .33 to your 2021 picks. It’s a mini SPAC half owned by Carl Icahn. Volume and price movement has been solid this week.
Market cap is around $23 million and they have $48 million in cash and $100 million NOL’s.
Can you make a chart for ENZN? It’s moved higher, with increasing volume, each day this week.
It’s a mini SPAC half owned by Carl Icahn
Thanks. Couchman is CEO of MYRX so that’s probably why he invested some of the company's money in ENZN. I’m excited to see how all this turns out. People are talking about Bill Ackmans SPAC since it’s been moving higher on possible deal speculation. That one has a market cap of $5 Billion. If ENZN even had only a $1 billion market cap, We would be looking at $13 a share. The potential is insane!
Yes, it’s really good news that Couchman hasn’t sold and moved on. I agree with you. I think Couchman probably has an idea of what Icahn is planning to do with ENZN. I really do have a feeling something will happen this year at the latest and maybe even in a few months.
Just with the $48 million cash and $100 million NOLs alone, ENZN should be over $1 IMO. What’s nice is that it will be very easy to move ENZN to a higher exchange when the time comes.
ENZN mini SPAC having a great week too. I think Carl Icahn will find a company to utilize it soon. Huge volume lately makes me think he might have a company in mind already IMO.
Is already at .33 and I own 100k shares of it! I think it could be a multi dollar stock. 2021 is going to be a great year!
I’m glad that we are in ENZN early. No one is talking about it that I know of so I think we have huge upside potential once it gets noticed and even more when it gets utilized.
I think Icahn will use ENZN as a mini SPAC as well. It’s crazy that the market cap is around $23 million or so but it has $48 million in cash and $100 million in NOL’s
There’s more... ENZN will get a $3.5 million milestone payment and estimated $3-$6 million a year for 10 years in royalty payments once SESNs bladder cancer drug is approved this year. The royalty payments could be more or less depending how well the drug does.
On a side note, I own just over 1 million MYRX shares. Last summer MYRX bought a 1.4% stake in ENZN (see filings). I’m still trying to figure that one out since MYRX is a shell stock.
MYRX recently bought 1.4% of ENZN so that could be the reason. Huge bid support here too
Great day for $ENZN!
Nice MYRX volume today. Nice grab by someone. Big blocks of shares like that are hard to come by.
That is very positive. Couchman is CEO of a shell stock MYRX that recently bought 1.4% of ENZN. Very interesting to say the least.
I see ENZN above $1 before a deal is even announced IMO
ENZN is perfect for a SPAC. Not only is it flush with cash and NOLs but it will be getting a 3.5 million milestone payment and 4-6 million a year in royalty payments each year for the next 10 years when Vicineum (sp) is approved by FDA
On huge volume too! We both own at least 100k shares and I think we could easily make over $200,000 each. ENZN has so much going for it. With Icahn clan on the BOD and Icahn himself owning 48% something will get done soon IMO. I’m sure Icahn will find a company to utilize this mini SPAC. So many more advantages for a profitable company to use ENZN instead of a normal SPAC.
Plus no one it talking about ENZN. It’s going to be an amazing 2021 for us!
ENZN over .30 now!
ENZN .30 now! Huge volume days yesterday and today
Awesome! Maybe we get at close of .30+
I think we slowly climb higher till news then it really takes off IMO
Go $ENZN!
I would keep the bid at .285. Don’t buy at the ask. I think you will get filled by tomorrow if not today when looking at the trading pattern over the last few days.
You will do quite well with those shares. ENZN should really be trading above $1 given that it’s market cap is $20 million even thought it has $48 million cash and $100 million NOLs (which will be worth more now that Dems are in control of everything now.
ENZN 100k bid at .285!
Although small, there is another pre market trade today for ENZN
It’s nice that none of the major shareholders have been selling. I have noticed someone selling 100k blocks of shares but I imagine whoever is selling those should be close to done since there has been lots of buying going on lately.
I’m really excited to see what happens with ENZN.
I really like what the outgoing CEO said yesterday. It makes me think that he knows something big is going to happen:
“Under the leadership of the Board and Rick, I have no doubt that Enzon has an impressive and exciting future,”
ENZN .25 mini SPAC news today:
Carl Icahn owns 48% of ENZN and a tiny shell MYRX .03 bought 1.4% of ENZN a few months ago.
Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon’s CFO, to Assume Position of CEO and Remain CFO
Press Release | 01/04/2021
CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Company’s Chief Executive Officer effective February 26, 2021. Andy joined Enzon in 2010 as Vice-President and General Counsel and has served as CEO since 2016. Upon Andy’s retirement, Richard L. Feinstein, Enzon’s Chief Financial Officer, will also assume the role of Chief Executive Officer and Secretary, as well as remain the Company’s Chief Financial Officer. Mr. Rackear will be available as a consultant to the Company following his retirement, as may be needed.
[img]“On behalf of the Board of Directors, I would like to thank Andy for his leadership and commitment to the company during his over 10 years with Enzon. Andy has led Enzon through its transition from a pharmaceutical company to a lean organization, and now with the completion of our rights offering, poised for future growth,” said Randolph Read, Chairman of the Enzon Board.
“It has been an honor and privilege leading Enzon through its transformative journey. Following the recent rights offering, the company is in a strong financial position. Under the leadership of the Board and Rick, I have no doubt that Enzon has an impressive and exciting future,” Rackear said.
About Enzon Pharmaceuticals
Enzon is positioned as a public company acquisition vehicle, where it can become an acquisition platform and more fully utilize its net operating loss carryforwards and enhance stockholder value.
ENZN news:
Richard L. Feinstein, Enzon’s CFO, to Assume Position of CEO and Remain CFO
Press Release | 01/04/2021
CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Company’s Chief Executive Officer effective February 26, 2021. Andy joined Enzon in 2010 as Vice-President and General Counsel and has served as CEO since 2016. Upon Andy’s retirement, Richard L. Feinstein, Enzon’s Chief Financial Officer, will also assume the role of Chief Executive Officer and Secretary, as well as remain the Company’s Chief Financial Officer. Mr. Rackear will be available as a consultant to the Company following his retirement, as may be needed.
“On behalf of the Board of Directors, I would like to thank Andy for his leadership and commitment to the company during his over 10 years with Enzon. Andy has led Enzon through its transition from a pharmaceutical company to a lean organization, and now with the completion of our rights offering, poised for future growth,” said Randolph Read, Chairman of the Enzon Board.
“It has been an honor and privilege leading Enzon through its transformative journey. Following the recent rights offering, the company is in a strong financial position. Under the leadership of the Board and Rick, I have no doubt that Enzon has an impressive and exciting future,” [/bred]Rackear said.
About Enzon Pharmaceuticals
Enzon is positioned as a public company acquisition vehicle, where it can become an acquisition platform and more fully utilize its net operating loss carryforwards and enhance stockholder value.
ENZN news:
Richard L. Feinstein, Enzon’s CFO, to Assume Position of CEO and Remain CFO
Press Release | 01/04/2021
CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Company’s Chief Executive Officer effective February 26, 2021. Andy joined Enzon in 2010 as Vice-President and General Counsel and has served as CEO since 2016. Upon Andy’s retirement, Richard L. Feinstein, Enzon’s Chief Financial Officer, will also assume the role of Chief Executive Officer and Secretary, as well as remain the Company’s Chief Financial Officer. Mr. Rackear will be available as a consultant to the Company following his retirement, as may be needed.
“On behalf of the Board of Directors, I would like to thank Andy for his leadership and commitment to the company during his over 10 years with Enzon. Andy has led Enzon through its transition from a pharmaceutical company to a lean organization, and now with the completion of our rights offering, poised for future growth,” said Randolph Read, Chairman of the Enzon Board.
“It has been an honor and privilege leading Enzon through its transformative journey. Following the recent rights offering, the company is in a strong financial position. Under the leadership of the Board and Rick, I have no doubt that Enzon has an impressive and exciting future,” [/bred]Rackear said.
About Enzon Pharmaceuticals
Enzon is positioned as a public company acquisition vehicle, where it can become an acquisition platform and more fully utilize its net operating loss carryforwards and enhance stockholder value.
ENZN news:
Richard L. Feinstein, Enzon’s CFO, to Assume Position of CEO and Remain CFO
Press Release | 01/04/2021
CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Company’s Chief Executive Officer effective February 26, 2021. Andy joined Enzon in 2010 as Vice-President and General Counsel and has served as CEO since 2016. Upon Andy’s retirement, Richard L. Feinstein, Enzon’s Chief Financial Officer, will also assume the role of Chief Executive Officer and Secretary, as well as remain the Company’s Chief Financial Officer. Mr. Rackear will be available as a consultant to the Company following his retirement, as may be needed.
“On behalf of the Board of Directors, I would like to thank Andy for his leadership and commitment to the company during his over 10 years with Enzon. Andy has led Enzon through its transition from a pharmaceutical company to a lean organization, and now with the completion of our rights offering, poised for future growth,” said Randolph Read, Chairman of the Enzon Board.
“It has been an honor and privilege leading Enzon through its transformative journey. Following the recent rights offering, the company is in a strong financial position. Under the leadership of the Board and Rick, I have no doubt that Enzon has an impressive and exciting future,” [/bred]Rackear said.
About Enzon Pharmaceuticals
Enzon is positioned as a public company acquisition vehicle, where it can become an acquisition platform and more fully utilize its net operating loss carryforwards and enhance stockholder value.
CELZ... wow what is causing all of these stocks to run so much? Dang I can’t wait till mine run like that. I could probably retire lol
$ENZN .28 mini SPAC half owned by Carl Icahn. $48 million in cash, $100 million NOL’s, and only $20 million market cap. No one talking about it right now.
I really do have a feeling ENZN will be utilized next year. It has the $48 million cash ready to use now. With the corporate tax rate likely going up to 28% next year, it will make NOL shells more valuable.